Movida Pharma Acquires China Rights to Cancer Drug from Cloaked Therapeutics

Monvida Pharma, a San Francisco-area oncology company, in-licensed China and Vietnam rights to TumorSelect® Paclitaxel from Cloaked Therapeutics of Mississippi.  TumorSelect ® Paclitaxel is a nanoparticle reformulation of paclitaxel; Cloaked believes the reformulation will improve paclitaxel's selectivity, improving its efficacy and lowering side effects. Details of the agreement were not disclosed. More details.... Share this with colleagues: // //